All posts by student

Cell Biology

New cancer treatment may be more effective than chemotherapy – The Independent

A newly discovered process to trigger the death of cancer cells could be more effective than current methods such as chemotherapy, scientists have said.

The new method of killing cancer cells, called Caspase Independent Cell Death (CICD), led to the complete eradication of tumours in experimental models.

Most current anti-cancer therapies (chemotherapy, radiation and immunotherapy) work by killing cancer cells through a process called apoptosis, which activates proteins called caspases, leading to cell death.

However in apoptosis, therapies often fail to kill all cancer cells, leading to disease recurrence, and can also have unwanted side effects that may even promote cancer.

Cancer Research's new ad is a live colonoscopy

Scientists from the University of Glasgow wanted to develop a way to improve therapy that induces cancer cell killing while also mitigating unwanted toxicity.

"Our research found that triggering Caspase-Independent Cell Death (CICD), but not apoptosis, often led to complete tumour regression.

"Especially under conditions of partial therapeutic response, as our experiments mimic, our data suggests that triggering tumour-specific CICD, rather than apoptosis, may be a more effective way to treat cancer," Dr Stephen Tait, Cancer Research UK Beatson Institute, from the Institute of Cancer Sciences, said.

Unlike apoptosis, which is a silent form of cell death, when cancer cells die through CICD, they alert the immune system through the release of inflammatory proteins.

The immune system can then attack the remaining tumour cells that evaded initial therapy-induced death.

In research published in Nature Cell Biology, the researchers used lab-grown colorectal cancer cells to show the advantage of killing cancer cells via CICD, however, these benefits may be applicable to a wide-range of cancer types.

Dr Tait added: "In essence, this mechanism has the potential to dramatically improve the effectiveness of anti-cancer therapy and reduce unwanted toxicity.

"Taking into consideration our findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation."

The paper was majority funded by Cancer Research UK.

Dr Justine Alford, Cancer Research UK's senior science information officer, said: "Although many cancer treatments work by triggering apoptosis, that method sometimes fails to finish the job and instead may lead to the tumour becoming harder to treat.

"This new research suggests there could be a better way to kill cancer cells which, as an added bonus, also activates the immune system. Now scientists need to investigate this idea further and, if further studies confirm it is effective, develop ways to trigger this particular route of cell death in humans."

Additional reporting by PA

Go here to read the rest:
New cancer treatment may be more effective than chemotherapy - The Independent

Cell Biology

Something in common: New JHU students discuss shared summer reading assignment, ‘Spare Parts’ – The Hub at Johns Hopkins

ByTaylor Jade Powell

Oscar, Cristian, Luis, and Lorenzo were never expected to amount to much. Born in Mexico and growing up in Arizona, the four undocumented teenagers were poor and attending an underfunded high school in the desert.

Though the students had never seen the ocean, two science teachers inspired them to build an underwater robot and compete in a marine robotics competition at the University of California, Santa Barbara.

Spare Parts: Four Undocumented Teenagers, One Ugly Robot, and the Battle for the American Dream tells the stories of young men with insurmountable odds stacked against themdeportation, prejudice, and a robotics team with 10 times more funding.

The book by Joshua Davis addresses the issue of immigration and challenges students to consider alternate ways of learning, said Tiffany Sanchez, Johns Hopkins University's interim dean of student life. That's why the Common Read Committee chose it as this year's assignment for the Class of 2021.

New students will discuss the book in small groups led by faculty, staff, resident assistants, and first-year mentors today as part of orientation.

"We hope this makes Hopkins feel a bit more like home and introduces new students to people and ideas that they might not normally come in contact with," Sanchez said.

Tiffany Sanchez

Interim dean of student life

The Common Read program started in 2007 with a mission to bring together first-year class members and new transfer students, while encouraging critical thinking and intellectual discussion. Each year a committee made up of JHU staff and faculty chooses a book that students receive via mail.

Over the summer, students had the opportunity to submit essays or short videos in response to the book, and this year there were more than 70 contest entries. Winners will be honored at the Common Read Keynote on Sept. 7, where protagonists Fredi Lajvardi and Oscar Vazquez will talk about their experiences depicted in the novel.

"It's such a great way to get to know our new students, and I enjoy learning about their lives," Sanchez said. "Each response reminded me that there are over 1,300 new individuals in our community and each of them comes with their own experiences, values, and ideas about the world."

One of three winners is Kelechi Nwankwoala, an incoming Writing Seminars and molecular cell biology double-major. In his contest submission, Nwankwoala said he considered his parents' immigration to America and his own fears of being treated differently because of his race as part of his response to the book.

"I tried to use narrative to express how racial prejudice and fear can become a constant weight on the psyche," he said. "It is my belief that constant fear does something to people; it effects the way you interact with the world. I wanted to illustrate how my own fears have changed over the years and how I have become more and more aware of the weight I shoulder."

Original post:
Something in common: New JHU students discuss shared summer reading assignment, 'Spare Parts' - The Hub at Johns Hopkins

Immunology

Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses – Science (subscription)

For flu vaccines, age matters

Development of a broad flu vaccine has been hampered by lack of clear insight into protective mechanisms across individuals to seasonal vaccines. Avey et al. perform a systems-level analysis on multiple influenza vaccination cohorts spanning distinct geographical locations and vaccination seasons and identify prevaccination predictive transcriptional signatures of influenza vaccination responses. They validated nine genes and three gene cohorts that associated with magnitude of antibody response in an independent cohort. However, these signatures were specific to young individuals and had an inverse correlation in older individuals. These data may help to predict antibody response to influenza vaccination, as well as provide insights into the distinct mechanism governing immune responses in young and older individuals.

Annual influenza vaccinations are currently recommended for all individuals 6 months and older. Antibodies induced by vaccination are an important mechanism of protection against infection. Despite the overall public health success of influenza vaccination, many individuals fail to induce a substantial antibody response. Systems-level immune profiling studies have discerned associations between transcriptional and cell subset signatures with the success of antibody responses. However, existing signatures have relied on small cohorts and have not been validated in large independent studies. We leveraged multiple influenza vaccination cohorts spanning distinct geographical locations and seasons from the Human Immunology Project Consortium (HIPC) and the Center for Human Immunology (CHI) to identify baseline (i.e., before vaccination) predictive transcriptional signatures of influenza vaccination responses. Our multicohort analysis of HIPC data identified nine genes (RAB24, GRB2, DPP3, ACTB, MVP, DPP7, ARPC4, PLEKHB2, and ARRB1) and three gene modules that were significantly associated with the magnitude of the antibody response, and these associations were validated in the independent CHI cohort. These signatures were specific to young individuals, suggesting that distinct mechanisms underlie the lower vaccine response in older individuals. We found an inverse correlation between the effect size of signatures in young and older individuals. Although the presence of an inflammatory gene signature, for example, was associated with better antibody responses in young individuals, it was associated with worse responses in older individuals. These results point to the prospect of predicting antibody responses before vaccination and provide insights into the biological mechanisms underlying successful vaccination responses.

Read more:
Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses - Science (subscription)

Neuroscience

Harvey forces sports changes…Stafford gets a new deal…NFL promoting neuroscience research – WCTI12.com

HOUSTON (AP) - Hurricane Harvey has forced both the Houston Astros and Houston Texans to play home games well away from home. It's left players wondering when they will be able to come back. The Astros will play a three-game series against the Texas Rangers at Tropicana Field in St. Petersburg, Florida, this week, starting Tuesday, and the Texans will wrap up their preseason NFL schedule against the Dallas Cowboys at AT&T Stadium in Arlington instead of NRG Stadium.

UNDATED (AP) - A big weekend college football game is also on the move due to Hurricane Harvey. The BYU-LSU game will be played Saturday night at the Superdome in New Orleans after massive flooding in Houston. The game is still scheduled to kick off at 9:30 p.m. Eastern and be televised on ESPN.

DETROIT (AP) - A person familiar with the deal says Matthew Stafford and the Detroit Lions have agreed to a $135 million, five-year extension that makes him the highest-paid player in the NFL. The person spoke to The Associated Press on condition of anonymity because terms were not disclosed. The team announced the deal keeps the quarterback under contract through the 2022 season. Detroit drafted Stafford No. 1 overall in 2009. He helped the Lions reach the playoffs last season for the third time in six seasons.

NEW YORK (AP) - A year after the NFL pledged $100 million in support of independent medical research and engineering advancements, a huge chunk of that soon will be awarded to such research, primarily dedicated to neuroscience. A Scientific Advisory Board assembled by the NFL is set to launch its program to solicit and evaluate research proposals for funding. The board will provide direction for the $40 million allocated under the league's initiative.

HAMILTON, Ontario (AP) - Ex Baylor coach Art Briles is having a little trouble with his job search in the wake of his firing over a sexual assault scandal allegedly involving some players. Less than 11 hours after the Hamilton Tiger-Cats of the Canadian Football League announced the hiring of Briles as an assistant coach, the league and the team backtracked in the face of public pressure and said he will not be joining the team after all.

See the original post:
Harvey forces sports changes...Stafford gets a new deal...NFL promoting neuroscience research - WCTI12.com

Neuroscience

NFL dedicates large portion of $100 million pledge to neuroscience – Christian Science Monitor

August 29, 2017NEW YORKA year after the NFL pledged $100 million in support of independent medical research and engineering advancements, a huge chunk of that soon will be awarded to such research, primarily dedicated to neuroscience.

A Scientific Advisory Board assembled by the NFL is set to launch its program to solicit and evaluate research proposals for funding. The board, comprised of independent experts, doctors, scientists, and clinicians, and chaired by retired US Army General Peter Chiarelli, will provide direction for the $40 million allocated under the league's initiative.

"Prevention should always be a focus," Mr. Chiarelli says. "Nevertheless, the development of biologically based diagnostics is critical for return-to-play decisions for the NFL, and return to combat/training for the armed forces. Imagine if you had a handheld analyzer that with a single drop could determine whether a player or a soldier had a concussion and determine the severity of that injury."

The NFL has an ongoing affiliation with the armed forces and in April partnered with the US Army Medical Research and Material Command on a three-year venture to collaborate on head health research and development.

Any sports-oriented medical studies must be all-encompassing. Developing improved tools for research and design is front and center, as the league's scientific advisory board is seeking to be, with significant financial outlay.

Doctors say CTE (chronic traumatic encephalopathy) can cause memory loss, depression, violent mood swings, and other cognitive and behavioral issues in those exposed to repetitive head trauma.

"There have been significant learnings in recent years that have changed the way we look at traumatic brain injury, notably CTE," says Dr. Allen Sills, who came aboard this year as the league's chief medical officer. "I agree with many medical experts that there are still a lot of unanswered questions relating to the cause, incidence, and prevalence of CTE. But what is clear is that there's a problem that impacts some athletes in sports like ours, others possibly, too, and we are eager to see CTE research move forward and begin to assemble more pieces of the puzzle.

"The NFL has a responsibility to do everything it can to make the game safer and drive research that advances treatment and prevention and, as we make advances, share them with the broader sports world. Most of the issues we face in the NFL are sport issues, and beyond that they are society issues."

A year out from Commissioner Roger Goodell's pledge to "look at anything and everything to protect our players and make the game safer," one of the areas receiving concentrated attention by the league is developing equipment that could provide even more specific and enhanced feedback on improving safety in football. Helmets, shoulder pads and other pads, and footwear all have seen improvements, but many believe there's much more to be done.

The league has embarked on what it calls "The Engineering Roadmap," a $60 million program designed to improve head protection equipment.

"This is a comprehensive and dedicated plan intended to spur innovation and significantly improve head protection for NFL players in three to five years," explains Dr. Jeffrey Crandall, director of the University of Virginia's Center for Applied Biomechanics and chair of the NFL's head, neck and spine engineering subcommittee.

The program is managed in collaboration with NFL Players Association's engineering consultants, Dr. Kristy Arbogast, co-scientific director of the Center for Injury Research and Prevention at Children's Hospital of Philadelphia, and Dr. Barry Myers, director of innovation at Duke University's Clinical and Translational Science Institute.

"A key component of the engineering roadmap is to accurately measure the motion and acceleration the head experiences during play in the NFL by player position, to give design direction for protective equipment," Dr. Arbogast says. "To date, we have been doing that via video reconstructions and injury event recreations using crash test dummies. These approaches are incredibly time intensive and, by design, focus on 'events' that must be subjectively selected from game film or injury reports."

But "the engineering roadmap leverages the modeling approach used in other fields to apply computational models to helmet design and evaluation," Dr. Crandall adds.

"Many fields have transitioned from primarily an experimental evaluation and design of products to a largely computational development program. Computational models that simulate various designs and use conditions can greatly enhance the thoroughness and efficacy of the design process while simultaneously reducing the time of product development."

Of note is a focus on sensors that can determine all sorts of data to help enhance safety. The league and the players' union are working to develop novel sensor technology capable of accurately recording the motion of the head during impact in varying game conditions and positions. The plan is for the NFL, when the technology is ready, to offer mouth guards instrumented with such sensors to players to measure their impact response.

"This athlete exposure data will inform the testing of protective equipment so that future helmet test methodologies and design evolution are relevant to what is actually experienced on the field," Arbogast says.

With a recent study into brain trauma stating that significant numbers of former NFL players are among those examined suffering from CTE, many say that the emphasis on injury prevention of all kinds must be paramount.

That means pushing hard on all fronts, particularly equipment innovation and testing.

Crandall sees the engineering roadmap as the correct, well, road to take.

"Beyond the particular outcome of the roadmap," he says, "we will develop an improved understanding of the types and severity of impacts players experience on-field through video analysis and sensors that will be available to examine a broader array of medical and engineering questions."

This story was reported by The Associated Press.

Read the original here:
NFL dedicates large portion of $100 million pledge to neuroscience - Christian Science Monitor

Genetics

The Genetics of Eating Disorders – Scientific American (blog)

Thirty million American women and men will struggle with eating disorders in their lifetime, and these life-threatening conditions have a higher mortality rate than any other psychiatric illness. For example, someone struggling with anorexia for five years has a 5 per cent, or one in20 chance, of dying.

While more and more people have come to understand that eating disorders are diseases of the brain, there's still awidespreadbeliefthat people with these devastating conditionsare vain, attention-seeking, or lacking in will power. But apaperjust published in Plos One makes it clear that this isn't true. The studyevaluated the genomes of95 individuals with diagnosed eating disorders andidentified 430 genes, clustered into two large groups, that are more likely to be damaged than in people without those disorders.

This adds to a growing body of research shows that eating disorders are powerful, biologically-driven illnesses. The new studysupports previous findings that the risk of developing an eating disorder is 50-80 per cent geneticthatpatientshave inherited damaged copies of genes that increase their risk of developing disordered eating. And understanding which genes are damaged can practitioners create better treatment treatment protocols.

In the PlosOne study, patients with eating disorders were clustered into two main groups. In the first, the damaged genes fell into a class of gut neuropeptides affecting that control appetite,food intakeand digestion/absorption of nutrients, making patients more likely to binge. Roughly half of this group struggled with restricted eating patterns, and the other half were binge eaters. The research confirms reports by our patients who believe their behavior is biologically driven.

The second group of patients had a cluster of genes involved in the function of the immune system and inflammation, which has long been known to suppress appetite. Patients with damaging mutations in the inflammation cluster are much more likely to have restricted-eating patterns. More research is needed to test a possible connection between eating disorders and auto-immune conditions like irritable bowel disease.

The new findings are consistent with known environmental eating disorder triggers. Faddieting, excessive exercise, or medical illness, are examples of negative energy states that have long been seen as possible eating disorder triggers. Negative energy states can set up behavioral changes like food binges or restricted food intake, triggering preexisting genetic drivers for eating disorders. Based on these findings, we argue that eating disorders are biologically driven illnesses that alter mood and behavior, similar to how the lack of thyroid hormone can result in depression in a patient with hypothyroidism.

Failure to understand the underlying causes of eating disorders creates stigma, making it less likely for those who struggle to get treatment. People with any medical condition deserve support and access to the best treatment. Someone with cancer wouldnt be denied treatment for their illness. Likewise, patients with eating disorders shouldnt feel guilty about their illness and they should have access to safe, effective treatment.

Biology isnt destiny. Eating disorders treatment is most effective if its accompanied by a general understanding that eating illnesses are biologically driven.

Lasting recovery from an eating disorder is possibleand those who struggle deserve understanding and support without guilt or judgment.

Read this article:
The Genetics of Eating Disorders - Scientific American (blog)

Genetics

Liverpool Women’s Hospital to increase genetic testing of babies – Liverpool Echo

Liverpool Womens Hospital is to expand its ability to genetically test newborn babies 12-fold.

The NHS Foundation Trust will be able to screen all infants for inherited conditions or illnesses and plan for early treatment as part of a major new IT project.

IT firm Novosco will introduce the computing system which also contribute to a major population health programme in Liverpool - analysing genetic information by location, identifying and enabling work to prevent localised health issues.

The role of genetics in healthcare is one of the most rapidly expanding areas of development for Liverpool Womens.

It provides a regional clinical genetics service covering a population of around 2.8 million people from across Merseyside, Cheshire and the Isle of Man.

Chief executive Kathryn Thomson posted on the trusts website: To discover that you or any child you have or plan to have may be at risk of a genetic disorder which could cause disability or a rare condition is traumatic.

People are sometimes shocked and anxious and wonder what the future might hold.

They need as much information and support as possible to help them cope.

That is why the often unsung work of our clinical genetics team is so important, providing diagnosis and supporting families when they need it most.

Novosco managing director Patrick McAliskey said: We are delighted to secure this contract which will enable the trust to take genetic testing to the next level and play an important role in the identification and prevention of conditions and illnesses in new-born babies and the wider population.

Original post:
Liverpool Women's Hospital to increase genetic testing of babies - Liverpool Echo

Genetics

Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors – Business Wire (press release)

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development. Tisotumab vedotin, an antibody-drug conjugate (ADC) targeting tissue factor, is currently being evaluated in Phase I/II clinical studies in solid tumors. Going forward, Genmab and Seattle Genetics will co-develop and share all future costs and profits for tisotumab vedotin on a 50:50 basis.

The combination of Genmabs differentiated HuMax-TF antibody and Seattle Genetics clinically-validated antibody-drug conjugate (ADC) technology has resulted in encouraging preliminary data for tisotumab vedotin in selected solid tumors. We very much look forward to working with Seattle Genetics to further develop this exciting first-in-class ADC product, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Our ADC partnership with Genmab has generated promising Phase I/II data for tisotumab vedotin in patients with recurrent cervical cancer. As Seattle Genetics opts into co-development of this clinical program, we add another potential product to our strong pipeline, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Together with Genmab, we look forward to advancing tisotumab vedotin for the treatment of solid tumors.

Preliminary data from the ongoing Phase I/II study of tisotumab vedotin in solid tumors (GEN701) were announced in June 2017, demonstrating antitumor activity and manageable safety in recurrent cervical cancer patients. This announcement can be found here. Updated preliminary data from the Phase I/II study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Spain), September 8-12, 2017.

Todays news does not impact the 2017 financial guidance issued by Genmab on May 10, 2017.

About the collaboration

In October 2011, Genmab and Seattle Genetics, Inc. entered into a commercial license and collaboration agreement for ADCs. Under the agreement, Genmab was granted rights to utilize Seattle Genetics ADC technology with its HuMax-TF antibody. Seattle Genetics was granted rights to exercise a co-development and co-commercialization option at the end of Phase I clinical development for tisotumab vedotin. With todays news Seattle Genetics exercises its option to co-develop tisotumab vedotin and the companies will share all future costs and profits for the product on a 50:50 basis. Seattle Genetics will be responsible for commercialization activities in the US, Canada, and Mexico, while Genmab will be responsible for commercialization activities in all other territories. Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other partys territories.

About tisotumab vedotin

Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of a human antibody that binds to tissue factor (TF) and Seattle Genetics ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). TF is a protein involved in tumor signaling and angiogenesis. Based on its high expression on many solid tumors and its rapid internalization, TF was selected as a target for an ADC approach. Tisotumab vedotin is in Phase I/II clinical studies for solid tumors.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, and the HexaBody platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit http://www.genmab.com.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The companys industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS (brentuximab vedotin), the companys lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs commercially available globally in 67 countries for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing enfortumab vedotin, an ADC for metastatic urothelial cancer, in a planned pivotal trial in collaboration with Astellas. Headquartered in Bothell, Washington, Seattle Genetics has a strong pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at http://www.seattlegenetics.com

Forward Looking Statement for Genmab

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; the DuoBody logo; the HexaBody logo; HuMax; HuMax-CD20; DuoBody; HexaBody and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX is a trademark of Janssen Biotech, Inc.

Forward Looking Statement for Seattle Genetics

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of tisotumab vedotin and its possible benefits and uses, and planned development activities including future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the inability to show sufficient activity and the risk of adverse events as tisotumab vedotin advances in clinical trials and regulatory actions. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the Securities and Exchange Commission.Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Original post:
Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors - Business Wire (press release)

Biochemistry

Biochemistry Analyzers Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis & Forecast … – DailyNewsKs

Biochemistry Analyzers Market Report covers the present scenario and the growth prospects of the Biochemistry Analyzers Industry for 2017-2022. Biochemistry Analyzers Market report analyses the industry potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, market demand and supply scenarios.

Biochemistry Analyzers Marketanalysis reports provide a valuable source of insightful data for business strategists and competitive analysis of Biochemistry Analyzers market. It provides the Biochemistry Analyzers industry overview with growth analysis and futuristic cost, revenue, demand and supply data. The research analysts provide an elaborate description of the value chain and its distributor analysis. This market study provides comprehensive data which enhances the understanding, scope and application of this report.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Biochemistry Analyzers Market Research Report@ http://www.360marketupdates.com/10979311

Biochemistry Analyzers Market Report provides comprehensive analysis of: Key market segments and sub-segments, evolving market trends and dynamics, changing supply and demand scenarios, Quantifying market opportunities through market sizing and market forecasting, Tracking current trends/opportunities/challenges, Competitive insights, Opportunity mapping in terms of technological breakthroughs

Major Manufacturers Analysis of Biochemistry Analyzers Market: URIT Medical Electronic, Rayto Life and Analytical Sciences, ELITechGroup, Rayto Life and Analytical Sciences, EKF Diagnostics, Shenzhen Genius Electronics, Spinreact, Mindray

Biochemistry Analyzers Market Regional Segment Analysis: North America, Europe, China, Japan, Southeast Asia, India

Biochemistry Analyzers Market Product Segment Analysis: Semi-Automatic Biochemical Analyzers, Automatic Analyzers, Type 3

Get Sample PDF of Biochemistry Analyzers Market Report @ https://www.360marketupdates.com/enquiry/request-sample/10979311

Biochemistry Analyzers Market Report Also Covers Marketing Strategy Analysis, Distributors/Traders & Market Effect Factors Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers of Biochemistry Analyzers Market: Biochemistry Analyzers Industrial Chain Analysis, Upstream Raw Materials Sourcing, Raw Materials Sources of Biochemistry Analyzers Major Manufacturers in 2015, Downstream Buyers

Biochemistry Analyzers Market: Marketing Strategy Analysis, Distributors/Traders

Marketing Channel: Direct Marketing, Indirect Marketing, Marketing Channel Development Trend included in Biochemistry Analyzers Market,

Market Positioning of Biochemistry Analyzers Market: Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List

Market Effect Factors Analysis: Technology Progress/Risk in Biochemistry Analyzers Market, Substitutes Threat, Technology Progress in Related Industry, Consumer Needs/Customer Preference Change, Economic/Political Environmental Change.

Any Query? Ask to our Expert @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/10979311

Biochemistry Analyzers market report provides pin-point analysis for changing competitive dynamics. It provides a forward-looking perspective on different factors driving or restraining market growth. Biochemistry Analyzers market report provides a six-year forecast assessed on the basis of how the market is predicted to grow. This market report helps in understanding the key product segments and their future.

About 360 Market Updates:

360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact

Mr. Ameya Pingaley360 Market Updates

+1 408 520 9750Emailsales@360marketupdates.com

See original here:
Biochemistry Analyzers Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis & Forecast ... - DailyNewsKs

Human Behavior

Safer manufacturing through materials science – University at Buffalo Reporter

Imagine a thriving community built around manufacturing jobswhere the production methods and processes not only minimize wasteand mitigate negative environmental impacts, but also addresshealth risks posed to residents and workers.

How do we get there? Who needs to have a seat at the table?

A new partnership, facilitated by The JPB Foundation, aims toaddress these questions and more through the formation of theCollaboratory for a Regenerative Economy (CoRE). Led by UBsDepartment of Materials Design and Innovation (MDI), CoRE is acollaboration with Clean Production Action and Niagara Share.

CoRE will bring together scientists, manufacturers, communitypartners and other key stakeholders to understand the challenges inbuilding a self-sustaining economy in rapidly expanding andevolving industries.

This is an unusual project with its emphasis onthe interplay between science, technology, and their interactionwith human behavior to impact social change, says KrishnaRajan, Erich Bloch Endowed Chair of MDI.

While the initial focus of the project is on solar panelmanufacturing, the findings will serve as a testbed that can laterbe scaled and used for other industries.

Our project seeks to lower the barriers to the adoptionof production processes that are environmentally friendly and offerthe potential to improve community health, Rajan says.

We will use cutting-edge discoveries in materials scienceand engineering to develop innovative and transformative approachesto design data-driven, green-manufacturing processes that willreduce the use of toxic chemicals and/or those derived from fossilfuels in the solar panel manufacturing industry, hesays.

This data-driven approach to designing alternate materials forindustrial use will include human and environmental healthfactors.

Our aim is to not only reduce the use of harmfulchemicals in industrial production, but also reduce the healthhazards arising from the exposure to toxic chemicals, both duringproduction and when products are decommissioned, says MarkRossi, executive director of Clean Production Action, which isbased in Somerville, Massachusetts.

Since low-income families make up a significant portion of thefrontline communities that are impacted by industrial and energyproduction, the project aligns closely with The JPBFoundations focus on health and poverty.

This unique partnership among the academic researchcommunity, non-governmental and community outreach organizationsbrings together complementary expertise in research, marketanalysis, policy formulation and social innovation tosupport the transition toward a safer materials economy,says Liesl Folks, dean of the School of Engineering and AppliedSciences.

Key features of the CoRE initiative include industry andcommunity-targeted workshops, an MDI Summer Institute and atraineeship program that links MDI students with communityorganizations and other constituencies.

A change agent program will provide industry andcommunity leaders with the tools needed to understand and analyzethese technologies, the inherent risks and cost-benefits involved,and the best methods for adopting new approaches.

The project embraces both scientific advancements andsocial innovation, underlining the importance of bringing togetherpeople and resources in new, more effective ways to createresilient networks that can drive new innovation and value for ourcommunities, businesses and local economies, says AlexandraMcPherson, principal of Niagara Share, a Buffalo-basednonprofit.

Adds Robin Schulze, dean of the College of Arts and Sciences:This project aligns with MDIs core mission ofaddressing societal needs through significant acceleration ofdesign and discovery of new materials in a socially responsiblemanner.

UBs Department of Materials Design and Innovation is acollaboration between the College of Arts and Sciences and theSchool of Engineering and Applied Sciences.

Read more from the original source:
Safer manufacturing through materials science - University at Buffalo Reporter